Skip to main content

Advertisement

SpringerLink
Log in

BAFF, a New Target for Intravenous Immunoglobulin in Autoimmunity and Cancer

  • Original Article
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Intravenous immunoglobulin (IVIg) has been used to treat autoimmune diseases and lymphoid malignancies with some therapeutic effect. In both these pathological conditions, there is an overproduction of BAFF (for “B-cell-activating factor of the TNF family”), and APRIL (for “a proliferation-inducing ligand”). The presence of antibodies (Abs) with BAFF and APRIL specificities in IVIg preparations was investigated by enzyme-linked immunosorbent assay, and Western Blot analysis. Apoptosis was measured by the annexin-V binding method, and confirmed using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling technique. Nonglycosylated recombinant BAFF, glycosylated affinity-purified BAFF, and recombinant APRIL (but not TNFα), were recognized by certain IgG in IVIg, and their F(ab′)2 fragments. Steric hindrance prevented the antiapoptotic effects of BAFF on B-lymphocytes. This work documents the presence of anti-BAFF and anti-APRIL Abs in IVIg. These can functionally neutralize the role of BAFF in B-cell survival. These anti-BAFF IgG might amend deleterious effects of BAFF in B-cell-mediated autoimmune diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.

Similar content being viewed by others

REFERENCES

  1. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755, 2001

    Article  PubMed  CAS  Google Scholar 

  2. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al.: Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117(Suppl):S525–S553, 2006

    Article  PubMed  CAS  Google Scholar 

  3. Toubi E, Kessel A, Shoenfeld Y: High-dose intravenous immunoglobulins: An option in the treatment of systemic lupus erythematosus. Hum Immunol 66:395–402, 2005

    Article  PubMed  CAS  Google Scholar 

  4. Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L, et al.: Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: An open-label study. Arthritis Rheum 50:1005–1007, 2004

    Article  PubMed  CAS  Google Scholar 

  5. Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, et al.: Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Arch Neurol 61:1515–1520, 2004

    Article  PubMed  Google Scholar 

  6. Chapel H, Dicato M, Gamm H, Brennan V, Ries F, Bunch C, et al.: Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: A comparison of two dose regimes. Br J Haematol 88:209–212, 1994

    PubMed  CAS  Google Scholar 

  7. Reed JC: Molecular biology of chronic lymphocytic leukemia. Semin Oncol 25:11–18, 1995

    Google Scholar 

  8. Chiorazzi N, Rai KR, Ferrarini M: Chronic lymphocytic leukemia. N Engl J Med 352:804–815, 2005

    Article  PubMed  CAS  Google Scholar 

  9. Sapir T, Shoenfeld Y: Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol 29:185–199, 2005

    Article  PubMed  CAS  Google Scholar 

  10. Youinou P, Jamin C, Pers JO, Berthou C, Saraux A, Renaudineau Y: B lymphocytes are required for development and treatment of autoimmune diseases. Ann NY Acad Sci 1050:19–33, 2005

    Article  PubMed  CAS  Google Scholar 

  11. Youinou P, Daridon C, Steinfeld S, Pers JO: A case for B-cells in the pathogenesis of Sjögren's syndrome. Trends Immunol (in press), 2007

  12. Ollila J, Vihinen M: B cells. Int J Biochem Cell Biol 37:518–523, 2005

    Article  PubMed  CAS  Google Scholar 

  13. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al.: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747–1756, 1999

    Article  PubMed  CAS  Google Scholar 

  14. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al.: BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260–263, 1999

    Article  PubMed  CAS  Google Scholar 

  15. Shu HB, Hu WH, Johnson H: TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 65:680–683, 1999

    PubMed  CAS  Google Scholar 

  16. Mukhopadhyay A, Ni J, Zhai Y, Yu GL, Aggarwal BB: Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem 274:15978–15981, 1999

    Article  PubMed  CAS  Google Scholar 

  17. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al.: Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20:785–798, 2004

    Article  PubMed  CAS  Google Scholar 

  18. Novak AJ, Bram RJ, Kay NE, Jelinek DF: Aberrant expression of B lymphocyte stimulator by B chronic lymphocytic leukemia cells: A mechanism for survival. Blood 100:2973–2979, 2002

    Article  PubMed  CAS  Google Scholar 

  19. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, et al.: BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201:195–200, 2005

    Article  PubMed  CAS  Google Scholar 

  20. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, et al.: APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188:1185–1190, 1998

    Article  PubMed  CAS  Google Scholar 

  21. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al.: Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6–10, 2001

    PubMed  CAS  Google Scholar 

  22. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S: Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54:192–201, 2006

    Article  PubMed  CAS  Google Scholar 

  23. Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmstrom P: Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 152:183–190, 2004

    Article  PubMed  CAS  Google Scholar 

  24. Shoenfeld Y, Krause I: IVIg for autoimmune, fibrosis, and malignant conditions: Our experience with 200 patients. J Clin Immunol 24:107–114, 2004

    Article  PubMed  CAS  Google Scholar 

  25. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, et al.: Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97:198–204, 2001

    Article  PubMed  CAS  Google Scholar 

  26. Pers JO, Devauchelle V, Bendaoud B, Saraux A, Jamin C, Youinou P: BLyS overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 1050:34–39, 2005

    Article  PubMed  CAS  Google Scholar 

  27. d’Arbonneau F, Pers JO, Devauchelle V, Pennec Y, Saraux A, Youinou P: BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjögren's syndrome. Arthritis Rheum 54:115–126, 2006

    Article  PubMed  CAS  Google Scholar 

  28. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415–1420, 1999

    Google Scholar 

  29. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501, 1992

    Article  PubMed  CAS  Google Scholar 

  30. Karpusas M, Cachero TG, Qian F, Boriack-Sjodin A, Mullen C, Strauch K, et al.: Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol 315:1145–1154, 2002

    Article  PubMed  CAS  Google Scholar 

  31. Cao P, Mei JL, Diao ZY, Zhang S: Expression, refolding and characterization of human soluble BAFF synthesized in Escherichia coli. Protein Expr Purif 41:199–206, 2005

    Article  PubMed  CAS  Google Scholar 

  32. Kurlander RJ, Hall J: Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 77:2010–2018, 1986

    PubMed  CAS  Google Scholar 

  33. Bendtzen K, Svenson M, Hansen M: Autoantibodies to cytokines in IVIG. J Rheumatol 20:2176–2177, 1993

    PubMed  CAS  Google Scholar 

  34. Rossi F, Kazatchkine MD: Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 143:4104–4109, 1989

    PubMed  CAS  Google Scholar 

  35. De Grandmont MJ, Racine C, Roy A, Lemieux R, Neron S: Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 101:3065–3073, 2003

    Article  PubMed  CAS  Google Scholar 

  36. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al.: Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161:3781–3790, 1998

    PubMed  CAS  Google Scholar 

  37. Rossi F, Sultan Y, Kazatchkine MD: Anti-idiotypes against autoantibodies and alloantibodies to VIIIC (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 74:311–316, 1988

    PubMed  CAS  Google Scholar 

  38. Miletic VD, Hester CG, Frank MM: Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J Immunol 156:749–757, 1996

    PubMed  CAS  Google Scholar 

  39. Leusch HG, Sitzler G, Markos-Pusztai S: Failure to demonstrate TNF alpha-specific autoantibodies in human sera by ELISA and Western Blot. J Immunol Methods 139:145–147, 1991

    Article  PubMed  CAS  Google Scholar 

  40. Swenson ER, Robertson HT, Hlastala MP: Effects of carbonic anhydrase inhibition on ventilation-perfusion matching in the dog lung. J Clin Invest 92:702–709, 1993

    PubMed  CAS  Google Scholar 

  41. Avrameas S: Natural autoantibodies: from “horror autotoxicus” to “gnothi seauton.” Immunol Today 12:154–159, 1991

    PubMed  CAS  Google Scholar 

  42. Hansen MB, Svenson M, Abell K, Yasukawa K, Diamant M, Bendtzen K: Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur J Immunol 25:348–354, 1995

    Article  PubMed  CAS  Google Scholar 

  43. Sundblad A, Marcos M, Huetz F, Freitas A, Heusser C, Portnoi D, et al.: Normal serum immunoglobulins influence the numbers of bone marrow pre-B and B cells. Eur J Immunol;21:1155–1161, 1991

    Article  PubMed  CAS  Google Scholar 

  44. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, et al.: BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169:4314–4321, 2002

    PubMed  CAS  Google Scholar 

  45. Bröker BM, Klajman A, Youinou P, Jouquan J, Worman CP, Murphy J, et al.: Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1:469–481, 1988

    Article  PubMed  Google Scholar 

  46. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: Disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 8:R6, 2006

    Article  PubMed  Google Scholar 

  47. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, et al.: Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103:679–688, 2004

    Article  PubMed  CAS  Google Scholar 

  48. Kalled SL: BAFF: a novel therapeutic target for autoimmunity. Curr Opin Investig Drugs 3:1005–1011, 2002

    PubMed  CAS  Google Scholar 

  49. Daridon C, Youinou P, Pers JO: BAFF, APRIL, TWE-PRIL: Who's who? Autoimmun Rev (in press), 2007

  50. Kalled SL, Ambrose C, Hou YM: The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun 8:206–242, 2005

    Article  PubMed  CAS  Google Scholar 

  51. Krause I, Blank M, Sherer Y, Gilburd B, Kvapil F, Shoenfeld Y: Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur J Immunol 32:3414–3424, 2002

    PubMed  CAS  Google Scholar 

  52. Shoenfeld Y, Rauova L, Gilburd B, Kvapil F, Goldberg I, Kopolovic J, Rovensky J, Blank M. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 14:1303–1311, 2002

    Article  PubMed  CAS  Google Scholar 

  53. Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ: Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 107:4540–4548, 2006

    Article  PubMed  CAS  Google Scholar 

  54. Lamoureux J, Aubin E, Lemieux R: Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: A role in the in vivo mechanisms of action of IVIg? Int Immunol 16:929–936, 2004

    Article  PubMed  CAS  Google Scholar 

  55. Ware CF: APRIL and BAFF connect autoimmunity and cancer. J Exp Med 192:F35–F37, 2000

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We acknowledge Cindy Séné and Simone Forest for their help with editing of this manuscript. Thanks are also due to Professor Peter M. Lydyard (London, UK) for critical reading of the text.

Author information

Authors and Affiliations

  1. Department of Immunopathology, Brest University Medical School, Brest, France

    Laëtitia Le pottier, Boutahar Bendaoud, Maryvonne Dueymes, Capucine Daridon, Pierre Youinou & Jacques-olivier Pers

  2. Department of Medicine “B”, Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel

    Yehuda Shoenfeld

  3. Laboratory of Immunology, Brest University Medical School Hospital, BP 824, F29609, Brest, France

    Pierre Youinou

Authors
  1. Laëtitia Le pottier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Boutahar Bendaoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maryvonne Dueymes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Capucine Daridon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pierre Youinou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yehuda Shoenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jacques-olivier Pers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Youinou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Le pottier, L., Bendaoud, B., Dueymes, M. et al. BAFF, a New Target for Intravenous Immunoglobulin in Autoimmunity and Cancer. J Clin Immunol 27, 257–265 (2007). https://doi.org/10.1007/s10875-007-9082-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-007-9082-2

KEY WORDS

Search

Navigation